Disclosures for "Clinical Profile for Lecanemab Subcutaneous Formulation for Treatment Initiation and Maintenance in Early Alzheimer’s Disease (AD)"
-
The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen.
-
Dr. Hersch has received personal compensation for serving as an employee of Eisai Inc.. Dr. Hersch has stock in Voyager Therapeutics. The institution of an immediate family member of Dr. Hersch has received research support from NIH. Dr. Hersch has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Penner has received personal compensation for serving as an employee of eisai. Dr. Penner has received personal compensation for serving as an employee of Zentalis. Dr. Penner has received personal compensation for serving as an employee of Biogen. Dr. Penner has stock in Biogen.
-
Dr. Bhagunde has received personal compensation for serving as an employee of Eisai.
-
Larisa Reyderman has nothing to disclose.
-
Author has nothing to disclose
-
Shobha Dhadda has received personal compensation for serving as an employee of Eisai Inc.
-
Dr. Irizarry has received personal compensation for serving as an employee of Eisai, Inc..
-
Dr. Kramer has received personal compensation for serving as an employee of Eisai Inc. Dr. Kramer has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Eisai Co., Ltd..